及时除颤与肾上腺素治疗对院内心脏骤停长期生存的影响
结果显示,室速/室颤患者及时除颤与1、3、5年生存率提高相关;无脉电活动/心室停搏患者及时肾上腺素仅与1年生存率提高相关,3年和5年无显著差异。
要点
- 室速/室颤患者及时除颤(≤2分钟)与1、3、5年生存率提高独立相关。
- 无脉电活动/心室停搏患者及时肾上腺素(≤5分钟)仅与1年生存率提高相关。
- 及时肾上腺素治疗的生存获益在3年和5年随访时未持续。
核心结论
- 室速/室颤所致院内心脏骤停患者,及时除颤与5年随访期内持续较高的长期生存率相关。
- 无脉电活动/心室停搏所致院内心脏骤停患者,及时肾上腺素治疗与1年生存率提高相关,但3年及5年时无显著获益。
研究设计与样本
- 室速/室颤患者按及时(≤2分钟)或延迟(>2分钟)除颤分层;无脉电活动/心室停搏患者按及时(≤5分钟)或延迟(>5分钟)肾上腺素治疗分层。
- 采用多变量分层改良Poisson回归模型评估及时治疗与长期生存的关联。
主要发现
- 室速/室颤患者中,及时除颤组1年生存率25.7%(1466/5714),延迟组15.5%(373/2405),调整RR 1.49(95%CI 1.32-1.69,P<0.0001)。
- 室速/室颤患者及时除颤组3年生存率19.1% vs 11.0%(调整RR 1.45,95%CI 1.23-1.69,P<0.0001),5年生存率14.7% vs 7.9%(调整RR 1.50,95%CI 1.22-1.83,P<0.0001)。
- 无脉电活动/心室停搏患者及时肾上腺素组3年生存率3.5% vs 2.9%(调整RR 1.17,95%CI 0.95-1.45,P=0.15),5年生存率2.3% vs 1.9%(调整RR 1.18,95%CI 0.88-1.58,P=0.27)。
临床怎么用
- 对室速/室颤所致院内心脏骤停,应确保及时除颤(≤2分钟)以改善长期生存。
- 对无脉电活动/心室停搏所致院内心脏骤停,及时肾上腺素(≤5分钟)可改善1年生存,但长期获益不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prior studies have reported higher in-hospital survival with prompt defibrillation and epinephrine treatment in patients with in-hospital cardiac arrest (IHCA). Whether this survival benefit persists after discharge is unknown. METHODS: We linked data from a national IHCA registry with Medicare files and identified 36 961 patients ≥65 years of age with an IHCA at 517 hospitals between 2000 and 2011. Patients with IHCA caused by pulseless ventricular tachycardia or ventricular fibrillation were stratified by prompt (≤2 minutes) versus delayed (>2 minutes) defibrillation, whereas patients with IHCA caused by asystole or pulseless electric activity were stratified by prompt (≤5 minutes) versus delayed (>5 minutes) epinephrine treatment. The association between prompt treatment and long-term survival for each rhythm type was assessed with multivariable hierarchical modified Poisson regression models. RESULTS: Of 8119 patients with an IHCA caused by ventricular tachycardia or ventricular fibrillation, the rate of 1-year survival was higher in those treated with prompt defibrillation than with delayed defibrillation (25.7% [1466 of 5714] versus 15.5% [373 of 2405]; adjusted relative risk [RR], 1.49; 95% confidence interval [CI] 1.32-1.69; P<0.0001). This survival advantage persisted at 3 years (19.1% versus 11.0%; adjusted RR, 1.45; 95% CI, 1.23-1.69; P<0.0001) and at 5 years (14.7% versus 7.9%; adjusted RR, 1.50; 95% CI, 1.22-1.83; P<0.0001). Of 28 842 patients with an IHCA caused by asystole/pulseless electric activity, the rate of 1-year survival with prompt epinephrine treatment was higher than with delayed treatment (5.4% [1341 of 24 885] versus 4.3% [168 of 3957]; adjusted RR, 1.20; 95% CI, 1.02-1.41; P=0.02), but this survival benefit was no longer present at 3 years (3.5% versus 2.9%; adjusted RR, 1.17; 95% CI, 0.95-1.45; P=0.15) and at 5 years (2.3% versus 1.9%; adjusted RR, 1.18; 95% CI, 0.88-1.58; P=0.27). CONCLUSIONS: Prompt defibrillation for IHCA caused by ventricular tachycardia or ventricular fibrillation was associated with higher rates of long-term survival throughout 5 years of follow-up, whereas prompt epinephrine treatment for asystole/pulseless electric activity was associated with greater survival at 1 year but not at 3 or 5 years. By quantifying the greater survival associated with timely defibrillation and epinephrine administration, these findings provide important insights into the durability of survival benefits for 2 process-of-care measures in current resuscitation guidelines.
引用
- Patel KK, Spertus JA, Khariton Y, et al. Association Between Prompt Defibrillation and Epinephrine Treatment With Long-Term Survival After In-Hospital Cardiac Arrest. Circulation. 2017. PMID: 29279412. doi:10.1161/CIRCULATIONAHA.117.030488
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。